CLDI Stock Earnings: Calidi Biotherapeutics Misses EPS for Q4 2023

Source: iQoncept / Shutterstock

Calidi Biotherapeutics (NYSEMKT:CLDI) just reported results for the fourth quarter of 2023.

Calidi Biotherapeutics reported earnings per share of -23 cents. This was below the analyst estimate for EPS of -20 cents.
The company did not report any revenue for the quarter.

biedexmarkets.com Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. biedexmarkets.com Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at [email protected].

Article printed from biedexmarkets.com Media, https://biedexmarkets.com.com/earning-results/2024/03/cldi-stock-earnings-calidi-biotherapeutics-for-q4-of-2023/.